Drug intelligence / Profile preview

SYN125

Development stage: Phase 1
Lead developer: Xingmeng Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SYN125 is a humanized IgG4 monoclonal antibody that targets and binds to the programmed cell death protein 1 (PD-1) receptor with high specificity and affinity. By inhibiting PD-1 and its downstream signaling pathways, SYN125 restores immune function through activation of T cells and T-cell-mediated immune responses against tumor cells. It is being developed primarily for the treatment of solid tumors and carcinomas. The drug is administered intravenously and has reached Phase 1 clinical trials in oncology indications.

Other names: anti-PD-1 monoclonal antibody SYN125anti-PD1 monoclonal antibody SYN125anti-PD 1 monoclonal antibody SYN125

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SYN125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYN125.

Explore the full profile